Game, set, match for factor VIII mismatch?

In this issue of Blood, Gunasekera et al provide evidence that the high rate of factor VIII (FVIII) inhibitors seen in black hemophilia A (HA) patients is not due to a mismatch between the structure of treatment products and FVIII genotypes common in blacks.

[1]  Patrizia Ricci,et al.  Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. , 2015, Blood.

[2]  R. Porcher,et al.  Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. , 2015, Blood.

[3]  M. Epstein,et al.  Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. , 2014, Blood.

[4]  J. Mahlangu,et al.  Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  C. Yanover,et al.  Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A , 2013, Nature Medicine.

[6]  C. Winkler,et al.  The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. , 2013, Blood.

[7]  M. Carrington,et al.  F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  R. Presley,et al.  Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  W. Hooper,et al.  F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  J. Goedert,et al.  A case–control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  L. Almasy,et al.  Inhibitors of factor VIII in black patients with hemophilia. , 2009, The New England journal of medicine.

[12]  N. Young,et al.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.

[13]  L. Aledort,et al.  Inhibitors occur more frequently in African–American and Latino Haemophiliacs , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  Masoud Parsania,et al.  THE PATIENTS , 1982, California state journal of medicine.